Hadgu Endale, Seifu Daniel, Tigneh Wondemagegnhu, Bokretsion Yonas, Bekele Abebe, Abebe Markos, Sollie Thomas, Merajver Sofia D, Karlsson Christina, Karlsson Mats G
Department of Biochemistry, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Department of Oncology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
BMC Womens Health. 2018 Feb 14;18(1):40. doi: 10.1186/s12905-018-0531-2.
Breast cancer is a heterogeneous disease with several morphological and molecular subtypes. Widely accepted molecular classification system uses assessment of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and proliferation marker Ki67. Few studies have been conducted on the incidence and molecular types of breast cancer in Sub-Saharan Africa. Previous studies mainly from Western and Central Africa, showed breast cancer to occur at younger ages and to present with aggressive features, such as high-grade, advanced stage and triple-negative phenotype (negative for ER, PR and HER2). Limited data from East Africa including Ethiopia however shows hormone receptor negative tumors to account for a lower proportion of all breast cancers than has been reported from elsewhere in Africa.
In this study from Tikur Anbessa Specialized Hospital, 114 breast cancer patients diagnosed between 2012 and 2015 were enrolled. ER, PR, Ki67 and HER2 receptor status were assessed using immunohistochemistry from tissue microarrays. FISH was used for assessment of gene amplification in all equivocal tumor samples and for confirmation in HER2-enriched cases.
The distribution of molecular subtypes was: Luminal A: 40%; Luminal B: 26%; HER2-enriched: 10%; TNBC: 23%. ER were positive in 65% of all tumors and 43% the cases were positive for PR. There was statistically significant difference in median age at diagnosis between the molecular subtypes (P < 0.05). There was a bimodal distribution of molecular subtypes in different age ranges with Luminal B subtype being more common at younger ages (median = 36) and Luminal A subtype more prevalent at older ages (median = 42). There were no statistically significant differences in tumor grade, histology, and stage between the molecular subtypes of breast cancer.
The present study detected Luminal A breast cancer to be the most common subtype and reveals a relatively low rate of hormone receptor negative and TNBC. Our findings and results from other East African studies suggest geographic variability in the distribution of the molecular subtypes of breast cancer in Africa and hence have important clinical and policy implications for breast cancer control and treatment in Ethiopia.
乳腺癌是一种具有多种形态学和分子亚型的异质性疾病。广泛接受的分子分类系统采用对雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2)和增殖标志物Ki67的评估。关于撒哈拉以南非洲地区乳腺癌的发病率和分子类型的研究较少。先前主要来自西非和中非的研究表明,乳腺癌发病年龄较轻,且具有侵袭性特征,如高级别、晚期和三阴性表型(ER、PR和HER2均为阴性)。然而,包括埃塞俄比亚在内的东非地区的有限数据显示,激素受体阴性肿瘤在所有乳腺癌中所占比例低于非洲其他地区的报道。
在这项来自提库尔·安贝萨专科医院的研究中,纳入了2012年至2015年间诊断的114例乳腺癌患者。使用组织微阵列通过免疫组织化学评估ER、PR、Ki67和HER2受体状态。对所有可疑肿瘤样本使用荧光原位杂交(FISH)评估基因扩增,并在HER2富集病例中进行确认。
分子亚型的分布为:管腔A型:40%;管腔B型:26%;HER2富集型:10%;三阴性乳腺癌(TNBC):23%。所有肿瘤中65%的ER呈阳性,43%的病例PR呈阳性。分子亚型之间诊断时的中位年龄存在统计学显著差异(P < 0.05)。在不同年龄范围内分子亚型呈双峰分布,管腔B型在较年轻年龄(中位年龄 = 36岁)更为常见,管腔A型在较年长年龄(中位年龄 = 42岁)更为普遍。乳腺癌分子亚型之间在肿瘤分级、组织学和分期方面无统计学显著差异。
本研究检测到管腔A型乳腺癌是最常见的亚型,并显示激素受体阴性和TNBC的发生率相对较低。我们的研究结果以及其他东非研究的结果表明,非洲乳腺癌分子亚型的分布存在地理差异,因此对埃塞俄比亚乳腺癌的控制和治疗具有重要的临床和政策意义。